These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22094366)

  • 1. The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance.
    Runge VM; Ai T; Hao D; Hu X
    Invest Radiol; 2011 Dec; 46(12):807-16. PubMed ID: 22094366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.
    Port M; Idée JM; Medina C; Robic C; Sabatou M; Corot C
    Biometals; 2008 Aug; 21(4):469-90. PubMed ID: 18344005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymeric gadolinium chelate magnetic resonance imaging contrast agents: design, synthesis, and properties.
    Ladd DL; Hollister R; Peng X; Wei D; Wu G; Delecki D; Snow RA; Toner JL; Kellar K; Eck J; Desai VC; Raymond G; Kinter LB; Desser TS; Rubin DL
    Bioconjug Chem; 1999; 10(3):361-70. PubMed ID: 10346865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tris(pyrone) chelates of Gd(III) as high solubility MRI-CA.
    Puerta DT; Botta M; Jocher CJ; Werner EJ; Avedano S; Raymond KN; Cohen SM
    J Am Chem Soc; 2006 Feb; 128(7):2222-3. PubMed ID: 16478170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging.
    Werner EJ; Datta A; Jocher CJ; Raymond KN
    Angew Chem Int Ed Engl; 2008; 47(45):8568-80. PubMed ID: 18825758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo evaluation of gadolinium hydroxypyridonate chelates: initial experience as contrast media in magnetic resonance imaging.
    Thompson MK; Misselwitz B; Tso LS; Doble DM; Schmitt-Willich H; Raymond KN
    J Med Chem; 2005 Jun; 48(11):3874-7. PubMed ID: 15916439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cleavable β-cyclodextrin nanocapsules incorporating Gd(III)-chelates as bioresponsive MRI probes.
    Martinelli J; Fekete M; Tei L; Botta M
    Chem Commun (Camb); 2011 Mar; 47(11):3144-6. PubMed ID: 21270985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of chelates in magnetic resonance imaging studies.
    Tripathi L; Kumar P; Singh R
    J Cancer Res Ther; 2009; 5(3):148-53. PubMed ID: 19841554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Stability" of gadolinium chelates.
    Tweedle MF
    Br J Radiol; 2007 Jul; 80(955):583-4; author reply 584-5. PubMed ID: 17704319
    [No Abstract]   [Full Text] [Related]  

  • 10. Environment-sensitive and enzyme-sensitive MR contrast agents.
    Querol M; Bogdanov A
    Handb Exp Pharmacol; 2008; (185 Pt 2):37-57. PubMed ID: 18626598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of thermodynamic and kinetic parameters in gadolinium chelate stability.
    Idée JM; Port M; Robic C; Medina C; Sabatou M; Corot C
    J Magn Reson Imaging; 2009 Dec; 30(6):1249-58. PubMed ID: 19938037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current uses of gadolinium chelates for clinical magnetic resonance imaging examination of the liver.
    Low RN
    Top Magn Reson Imaging; 1998 Jun; 9(3):141-66. PubMed ID: 9621404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AAZTA-based bifunctional chelating agents for the synthesis of multimeric/dendrimeric MRI contrast agents.
    Gugliotta G; Botta M; Tei L
    Org Biomol Chem; 2010 Oct; 8(20):4569-74. PubMed ID: 20740241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of approved MR contrast media for intravenous injection.
    Runge VM
    J Magn Reson Imaging; 2000 Aug; 12(2):205-13. PubMed ID: 10931582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
    Idée JM; Port M; Dencausse A; Lancelot E; Corot C
    Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
    Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
    Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for the covalent conjugation of a bifunctional chelating agent to albumin: synthesis and characterization of potential MRI contrast agents.
    Kundu A; Peterlik H; Krssak M; Bytzek AK; Pashkunova-Martic I; Arion VB; Helbich TH; Keppler BK
    J Inorg Biochem; 2011 Feb; 105(2):250-5. PubMed ID: 21194625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of linear and macrocyclic gadolinium based contrast agents.
    Schmitt-Willich H
    Br J Radiol; 2007 Jul; 80(955):581-2; author reply 584-5. PubMed ID: 17704318
    [No Abstract]   [Full Text] [Related]  

  • 19. Fast and easy access to efficient bifunctional chelators for MRI applications.
    Gugliotta G; Botta M; Giovenzana GB; Tei L
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3442-4. PubMed ID: 19477128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of molecular descriptors in the design of gadolinium (III) chelates as MRI contrast agents.
    Maiocchi A
    Mini Rev Med Chem; 2003 Dec; 3(8):845-59. PubMed ID: 14529503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.